First Trust Advisors
EWTX icon

First Trust Advisors’s Edgewise Therapeutics EWTX Stock Holding History

First Trust Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
9,877
+748
+8% +$25.8K ﹤0.01% 2459
2026
Q1 		$288K Buy
+9,129
New +$263K ﹤0.01% 2477

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors's EWTX Position: Q2 2026 in Review

First Trust Advisors increased its Edgewise Therapeutics (EWTX) stake by 8.2% in Q2 2026, buying an estimated $25.8K and bringing the position to 9,877 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

First Trust Advisors first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • First Trust Advisors held 9,877 shares of Edgewise Therapeutics worth $401K as of Q2 2026.
  • First Trust Advisors bought 748 Edgewise Therapeutics shares in Q2 2026, an estimated $25.8K.
  • Edgewise Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2459 holding.
  • First Trust Advisors first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.